Statistical cure fraction in patients with borderline resectable pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy followed by radical resection: a secondary analysis of reconstructed individual patient data
{{output}}
Purpose: Although neoadjuvant therapy (NAT) has been applied in patients with borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC), limited data on long-term outcomes are available to support its role as a potentially... ...
